U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C53H90O22
Molecular Weight 1079.2685
Optical Activity UNSPECIFIED
Defined Stereocenters 29 / 29
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GINSENOSIDE RC

SMILES

[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(C)(C)[C@]4([H])CC[C@@]23C)[C@](C)(CCC=C(C)C)O[C@@H]7O[C@H](CO[C@@H]8O[C@@H](CO)[C@H](O)[C@H]8O)[C@@H](O)[C@H](O)[C@H]7O

InChI

InChIKey=JDCPEKQWFDWQLI-LUQKBWBOSA-N
InChI=1S/C53H90O22/c1-23(2)10-9-14-53(8,75-47-43(67)39(63)37(61)29(72-47)22-68-45-41(65)36(60)28(21-56)69-45)24-11-16-52(7)33(24)25(57)18-31-50(5)15-13-32(49(3,4)30(50)12-17-51(31,52)6)73-48-44(40(64)35(59)27(20-55)71-48)74-46-42(66)38(62)34(58)26(19-54)70-46/h10,24-48,54-67H,9,11-22H2,1-8H3/t24-,25+,26+,27+,28-,29+,30-,31+,32-,33-,34+,35+,36-,37+,38-,39-,40-,41+,42+,43+,44+,45+,46-,47-,48-,50-,51+,52+,53-/m0/s1

HIDE SMILES / InChI

Molecular Formula C53H90O22
Molecular Weight 1079.2685
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 29 / 29
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.lktlabs.com/product/ginsenoside-rc/ https://www.ncbi.nlm.nih.gov/pubmed/26981165

Ginsenoside Rc is a triterpene saponin originally found in species of Panax that exhibits antioxidative, anti-aging, antinociceptive, and anti-diabetic activities. Ginsenoside Rc inhibits phosphorylation of Foxo1, inhibits AMPK, activates PI3K/Akt signaling, and increases levels of catalase, decreasing oxidative stress. Ginsenoside Rc also induces antinociception in animal models of writhing and formalin-induced pain, potentially through activity on transient receptor potential vanilloid 1 (TRPV1) channels. In other animal models, ginsenoside Rc activates AMPK and p38 MAPK, increasing glucose uptake. Additionally, this compound increases the life span of Caenorhabditis elegans. Ginsenoside Rc has being shown to attenuate inflammatory symptoms in CIA, EtOH/HCl-mediated gastritis, and LPS/D-galactosamine (D-GalN)-triggered hepatitis without altering toxicological parameters, and without inducing gastric irritation. These anti-inflammatory effects were accompanied by the suppression of TNF-a and IL-6 production and the induction of anti-inflammatory cytokine IL-10 in mice with CIA. Ginsenoside Rc also attenuated the increased levels of luciferase activity by IRF-3 and AP-1, reduced TBK1, IRF-3, and ATF2 phosphorylation in the joint and liver tissues of mice with hepatitis. Ginsenoside Rc may be a major component of Korean Red Ginseng, marketed in Korea, with useful anti-inflammatory properties due to its suppression of IRF-3 and AP-1 pathways. Korean ginseng (Panax ginseng Meyer, Araliaceae) is traditionally used as an important herbal medicine in Far East Asia. Korean Red Ginseng is possibly effective for:

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Purification and characterization of new special ginsenosidase hydrolyzing multi-glycisides of protopanaxadiol ginsenosides, ginsenosidase type I.
2007 Feb
Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
2015 Feb
Patents

Patents

Sample Use Guides

KRG extract contained 1.80mg/g Ginsenoside Rc, as well as ginsenoside-Rb1: 4.26mg/g, -B2: 1.71 mg/g, -Rb2: 1.62mg/g, -Rd: 0.29mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules (500 mg/dose) were taken daily for 12 weeks
Route of Administration: Oral
Ginsenoside Rc inhibits MMP-13 expression in IL-1β-treated SW1353 cells at non-cytotoxic concentration (30 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:02:59 GMT 2023
Edited
by admin
on Sat Dec 16 08:02:59 GMT 2023
Record UNII
0K83B0L786
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GINSENOSIDE RC
Common Name English
PANAXOSIDE RC
Common Name English
NSC-310104
Code English
.BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,12.BETA.)-20-((6-O-.ALPHA.-L-ARABINOFURANOSYL-.BETA.-D-GLUCOPYRANOSYL)OXY)-12-HYDROXYDAMMAR-24-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANOSYL-
Systematic Name English
GINSENOSIDE RC (CONSTITUENT OF AMERICAN GINSENG, ASIAN GINSENG, AND TIENCHI GINSENG) [DSC]
Common Name English
Code System Code Type Description
NSC
310104
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
PUBCHEM
12855889
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
ECHA (EC/EINECS)
234-253-5
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
FDA UNII
0K83B0L786
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
CHEBI
77154
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
EPA CompTox
DTXSID60911542
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
CAS
11021-14-0
Created by admin on Sat Dec 16 08:03:00 GMT 2023 , Edited by admin on Sat Dec 16 08:03:00 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
PARENT -> CONSTITUENT ALWAYS PRESENT
USP
PARENT -> CONSTITUENT ALWAYS PRESENT
USP